https://mindmedicinelaw.com/briefing/fda-revises-guidance-on-tds-for-andas-implications-for-psychedelics-20260803-28632The Psychedelic Journalen2026-08-03T15:06:14.347459+00:00FDA Revises Guidance on TDS for ANDAs: Implications for PsychedelicsFDA guidance, transdermal delivery systems, ANDAs, psychedelic compounds, skin irritation studies, drug approval process, in vivo studies, sensitization potential, drug delivery safety, psychedelic researchhttps://mindmedicinelaw.com/briefing/dea-s-expanded-listing-for-pmk-glycidic-acid-implications-20260803-28604The Psychedelic Journalen2026-08-03T15:06:00.405231+00:00DEA's Expanded Listing for PMK Glycidic Acid: ImplicationsDEA, PMK glycidic acid, list I chemicals, MDMA synthesis, chemical regulation, research compliance, Controlled Substances Act, chemical manufacturing, drug enforcement, precursor chemicalshttps://mindmedicinelaw.com/briefing/pilot-study-on-aspirin-ketamine-for-knee-pain-management-20260801-28689The Psychedelic Journalen2026-08-03T15:06:25.728489+00:00Pilot Study on Aspirin & Ketamine for Knee Pain Managementaspirin, ketamine, pain management, knee surgery, clinical trials, postoperative care, multimodal pain relief, opioid alternatives, NMDA receptor antagonist, acute painhttps://mindmedicinelaw.com/briefing/htr2a-gene-s-role-in-psychedelic-effects-and-research-20260801-28514The Psychedelic Journalen2026-08-02T22:05:09.425941+00:00HTR2A Gene's Role in Psychedelic Effects and ResearchHTR2A gene, psychedelic effects, cortical changes, serotonin receptor, therapeutic applications, transcriptomic studies, neural cell cultures, Allen Human Brain Atlas, mental health treatment, psychedelic-assisted therapyhttps://mindmedicinelaw.com/briefing/psychedelic-pharmacology-s-role-in-neuropsychiatric-drug-development-20260801-28421The Psychedelic Journalen2026-08-02T15:05:04.947799+00:00Psychedelic Pharmacology's Role in Neuropsychiatric Drug Developmentpsychedelic pharmacology, neuropsychiatric drug development, mental health disorders, clinical trials, psychedelic research, psilocybin, MDMA, neuroplasticity, psychiatric care, safety evaluationshttps://mindmedicinelaw.com/briefing/new-model-for-estimating-e-i-balance-via-m-eeg-20260731-28515The Psychedelic Journalen2026-08-02T22:05:24.021452+00:00New Model for Estimating E/I Balance via M/EEGexcitation inhibition balance, M/EEG recordings, schizophrenia research, psychiatric disorders, synaptopathy, personalized interventions, neuroscience, clinical trials, brain function, psychedelic researchhttps://mindmedicinelaw.com/briefing/psychedelic-informed-therapeutics-for-depression-a-new-frontier-20260731-28181The Psychedelic Journalen2026-08-01T22:07:09.855319+00:00Psychedelic-informed Therapeutics for Depression: A New Frontierpsychedelic therapeutics, depression treatment, synaptic plasticity, inflammation-plasticity coupling, psychoplastogens, ketamine, serotonergic psychedelics, rapid-acting antidepressants, biomarker-guided treatment, neuroinflammationhttps://mindmedicinelaw.com/briefing/experience-trajectory-framework-enhancing-psychedelic-safety-20260731-28204The Psychedelic Journalen2026-08-01T22:06:46.122997+00:00Experience-Trajectory Framework: Enhancing Psychedelic Safetypsychedelic therapy, experience-trajectory framework, substance-specific risk, safety protocols, baseline risk state, clinical trials, neuroscience, public health, preparation standards, aftercarehttps://mindmedicinelaw.com/briefing/esketamine-s-role-in-reducing-post-cesarean-sleep-disorders-20260731-28191The Psychedelic Journalen2026-08-01T22:06:26.895293+00:00Esketamine's Role in Reducing Post-Cesarean Sleep Disordersesketamine, postoperative sleep disorders, cesarean section, obstetric anesthesia, postpartum depression, analgesic efficacy, clinical guidelines, anesthesia management, NMDA receptor antagonist, maternal-neonatal complicationshttps://mindmedicinelaw.com/briefing/magnesium-s-impact-on-cortical-neuron-dynamics-new-insights-20260730-28519The Psychedelic Journalen2026-08-02T22:05:31.685172+00:00Magnesium's Impact on Cortical Neuron Dynamics: New Insightsmagnesium, neuronal dynamics, burstiness, NMDA receptors, neurological disorders, cortical cultures, information processing, brain health, therapeutic applications, neuroscience researchhttps://mindmedicinelaw.com/briefing/us-psilocybin-legalization-state-efforts-and-global-impact-20260730-28487The Psychedelic Journalen2026-08-02T22:05:16.185161+00:00US Psilocybin Legalization: State Efforts and Global Impactpsilocybin legalization, US policy, state initiatives, psychedelic research, global model, activism, investment, therapeutic use, legal framework, federal roadblockshttps://mindmedicinelaw.com/briefing/psychedelic-therapy-for-racial-trauma-a-new-study-in-jamaica-20260730-28484The Psychedelic Journalen2026-08-02T22:05:01.031100+00:00Psychedelic Therapy for Racial Trauma: A New Study in Jamaicapsychedelic therapy, racial trauma, cultural safety, community affirmation, psilocybin, neuroplasticity, mental health, race-based traumatic stress, culturally responsive care, Healing Racial Trauma Protocolhttps://mindmedicinelaw.com/briefing/childhood-trauma-s-impact-on-psychedelic-outcomes-explored-20260730-28148The Psychedelic Journalen2026-08-02T15:05:46.767116+00:00Childhood Trauma's Impact on Psychedelic Outcomes Exploredchildhood trauma, psychedelic outcomes, psilocybin, ayahuasca, MDMA, trauma-informed research, cultural inclusivity, psychological risks, therapeutic potential, mental healthhttps://mindmedicinelaw.com/briefing/global-study-connects-breathwork-to-enhanced-mental-well-being-20260730-28149The Psychedelic Journalen2026-08-02T15:05:37.038665+00:00Global Study Connects Breathwork to Enhanced Mental Well-beinghigh ventilation breathwork, experiential avoidance, altered states of consciousness, mental well-being, therapeutic practices, cross-sectional study, emotional breakthroughs, mental health interventionshttps://mindmedicinelaw.com/briefing/photoswitchable-orexin-antagonist-a-new-tool-for-brain-studies-20260730-28182The Psychedelic Journalen2026-08-02T15:05:29.056938+00:00Photoswitchable Orexin Antagonist: A New Tool for Brain Studiesorexin receptor, photoswitchable antagonist, psychiatric disorders, optical control, brain signaling, neuroscience research, photorexant, in vitro studies, mouse brain studies, psychedelic researchhttps://mindmedicinelaw.com/briefing/psychological-distress-and-cancer-immunotherapy-response-20260730-28183The Psychedelic Journalen2026-08-02T15:05:20.911441+00:00Psychological Distress and Cancer Immunotherapy Responsepsychological distress, cancer immunotherapy, immune response, biomarkers, psycho-neuro-immune interactions, clinical trialshttps://mindmedicinelaw.com/briefing/dmt-s-impact-on-consciousness-new-study-insights-20260730-28208The Psychedelic Journalen2026-08-02T15:05:13.863192+00:00DMT's Impact on Consciousness: New Study InsightsDMT, consciousness, pharmacodynamics, brain dynamics, psychedelic research, therapeutic applications, alpha-band activity, functional connectivity, neuroscience, clinical trialshttps://mindmedicinelaw.com/briefing/dmt-s-impact-on-consciousness-new-study-insights-20260730-28206The Psychedelic Journalen2026-08-01T22:06:53.787131+00:00DMT's Impact on Consciousness: New Study InsightsDMT, consciousness, brain connectivity, psychedelic research, pharmacodynamics, neuroscience, clinical trials, public health, serotonergic psychedelics, perception reorganizationhttps://mindmedicinelaw.com/briefing/mb-pat-in-canada-a-new-model-for-cancer-demoralization-20260730-28184The Psychedelic Journalen2026-08-01T22:06:36.497411+00:00MB-PAT in Canada: A New Model for Cancer Demoralizationmindfulness-based therapy, psilocybin-assisted therapy, cancer demoralization, Canadian oncology, group therapy model, psychedelic researchhttps://mindmedicinelaw.com/briefing/esketamine-s-role-in-pediatric-anesthesia-new-findings-20260728-27857The Psychedelic Journalen2026-08-02T22:05:38.684057+00:00Esketamine's Role in Pediatric Anesthesia: New Findingsesketamine, pediatric anesthesia, limb withdrawal, rocuronium, anesthesia protocols, dose-dependent effects, Hangzhou Children's Hospital, adverse reactions, patient safety, clinical trialshttps://mindmedicinelaw.com/briefing/fungal-metabolites-in-tauopathy-treatment-new-insights-20260728-28189The Psychedelic Journalen2026-08-01T22:07:01.511495+00:00Fungal Metabolites in Tauopathy Treatment: New Insightsfungal metabolites, tauopathies, autophagy modulators, neurodegenerative diseases, computational drug discovery, psychedelic compoundshttps://mindmedicinelaw.com/briefing/evaluating-glycyrrhiza-glabra-s-anxiolytic-potential-20260725-27693The Psychedelic Journalen2026-08-03T15:06:40.203327+00:00Evaluating Glycyrrhiza glabra's Anxiolytic Potentialglycyrrhiza glabra, anxiolytic effects, canrenoic acid, natural therapeutics, anxiety treatment, clinical trials, pharmacological evaluation, CNS modulation, mental health, phytochemical profilinghttps://mindmedicinelaw.com/briefing/synergistic-effects-of-dds-and-nac-in-spinal-cord-injury-pain-20260723-27697The Psychedelic Journalen2026-08-03T15:06:55.922059+00:00Synergistic Effects of DDS and NAC in Spinal Cord Injury Paindapsone, N-acetylcysteine, neuropathic pain, spinal cord injury, oxidative stress, preclinical study, synergistic effects, pain management, clinical trials, antioxidant therapyhttps://mindmedicinelaw.com/briefing/chemsex-patterns-in-msm-sex-workers-vs-content-creators-20260722-27701The Psychedelic Journalen2026-08-03T15:07:07.673993+00:00Chemsex Patterns in MSM Sex Workers vs. Content Creatorschemsex, MSM sex workers, digital content creators, harm reduction, public health, psychoactive substances, occupational context, substance use patterns, clinical outreach, tailored interventions